PDF(Pubmed)
Abstract：
A heterologous Ad26/MVA vaccine was given prior to an analytic treatment interruption (ATI) in people living with HIV-1 (mainly CRF01_AE) who initiated antiretroviral treatment (ART) during acute HIV-1. We investigate the impact of Ad26/MVA vaccination on antibody (Ab)-mediated immune responses and their effect on time to viral rebound. The vaccine mainly triggers vaccine-matched binding Abs while, upon viral rebound post ATI, infection-specific CRF01_AE binding Abs increase in all participants. Binding Abs are not associated with time to viral rebound. The Ad26/MVA mosaic vaccine profile consists of correlated non-CRF01_AE binding Ab and Fc effector features, with strong Ab-dependent cellular phagocytosis (ADCP) responses. CRF01_AE-specific ADCP responses (measured either prior to or post ATI) are significantly higher in individuals with delayed viral rebound. Our results suggest that vaccines eliciting cross-reactive responses with circulating viruses in a target population could be beneficial and that ADCP responses may play a role in viral control post treatment interruption.
摘要：
在急性HIV-1期间启动抗逆转录病毒治疗（ART）的HIV-1感染者（主要是CRF01_AE）的分析治疗中断（ATI）之前，给予异源Ad26/MVA疫苗。我们研究了Ad26/MVA疫苗接种对抗体（Ab）介导的免疫反应的影响及其对病毒反弹时间的影响。疫苗主要触发疫苗匹配的结合抗体，而，在ATI后病毒反弹后，感染特异性CRF01_AE结合抗体在所有参与者中增加。结合Ab与病毒反弹的时间无关。Ad26/MVA镶嵌疫苗谱由相关的非CRF01_AE结合Ab和Fc效应子特征组成，具有强烈的Ab依赖性细胞吞噬作用（ADCP）反应。CRF01_AE特异性ADCP应答(在ATI之前或之后测量)在具有延迟病毒反弹的个体中显著更高。我们的结果表明，在目标人群中引发与循环病毒交叉反应反应的疫苗可能是有益的，并且ADCP反应可能在治疗中断后的病毒控制中起作用。
